Monte Rosa Therapeutics GLUE 深 滬
等待開盤 08-21 09:30:00 美东时间
4.43
+0.030
+0.68%
華盛通- 最 高4.50
- 今 開4.40
- 成交量 39.49万股
- 最 低 4.33
- 昨 收 4.40
- 總市值 2.72亿
- 52周最高 12.40
- 市盈率 靜 --
- 換手率 0.64%
- 52周最低 3.5001
- 委 比 -36.11%
- 總股本 6150.98万
- 歷史最高 45.56
- 量 比 0.95
- 振 幅 3.86%
- 歷史最低 2.44
- 每 手 1
- 風險率 1.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Monte Rosa Therapeutics Q2 EPS $(0.15) Beats $(0.39) Estimate, Sales $23.19M Beat $10.80M Estimate
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.39) by 61.14 percent. This is a 65.12 percent increase over losses of $(0.43) per
08-07 19:21
Monte Rosa Announces First Subjects Dosed In Phase 1 Study Evaluating MRT-8102, NEK7-Directed MGD Being Developed For Treatment Of Inflammatory Conditions Driven By NLRP3 Inflammasome, IL-1β, And IL-6; Initial Results From Phase 1 Study Expected In H1 2026
MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic
07-21 19:07
编码器-解码器架构的复兴？谷歌一口气发布32个T5Gemma模型
（转自：机器之心） 机器之心报道 编辑：Panda 今天是 xAI 的大日子，伊隆・马斯克早早就宣布了会在今天发布 Grok 4 大模型，AI 社区的眼球也已经...
07-10 16:35
Monte Rosa Therapeutics Announces The Publication Of Groundbreaking New Discoveries Featured On The Cover Of Science, Titled "Mining The CRBN Target Space Redefines Rules For Molecular Glue-Induced Neosubstrate Recognition"
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the publication of groundbreaking new discoveries
07-04 02:16
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
Monte Rosa Therapeutics has published a groundbreaking study in *Science* detailing how their AI/ML-powered QuEEN™ engine expands the target space for molecular glue degraders (MGDs), identifying over 100 previously undruggable protein targets. These discoveries unlock new opportunities in treating historically intractable diseases in oncology, immunology, and inflammation, demonstrating the engine's ability to design highly selective degrader th...
07-03 18:15
国际权威认证！凌云光通过CMMI四级评估
近期， 凌云光成功通过国际公认最权威的软件研发管理体系认证——CMMI（软件能力成熟度模型集成）DEV四级评估， 这标志着公司在软件研发过程管理能力、项目交付质...
06-23 17:02
FDA Clears IND Application For Monte Rosa Therapeutics' MRT-8102, NEK7-Directed MGD Developed To Treat Inflammatory Conditions Linked To NLRP3, IL-1β, And IL-6 Dysregulation
MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa's clinical I&I portfolioPotency,
06-10 19:04
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
Monte Rosa Therapeutics announced FDA clearance for MRT-8102, a NEK7-targeting molecular glue degrader (MGD) for treating inflammatory diseases linked to NLRP3, IL-1β, and IL-6 dysregulation. The company plans to initiate a Phase 1 study shortly, with initial results expected in H1 2026. Preclinical studies demonstrate MRT-8102's potency, selectivity, and long-lasting pharmacodynamics, supporting its potential to address多种 inflammatory conditions...
06-10 11:00
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotech company focused on molecular glue degrader (MGD)-based medicines, announced that CEO Markus Warmuth, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, at 12:50 p.m. EDT. A webcast will be available via Monte Rosa’s website, with an archive accessible for 30 days post-event. The company specializes in MGDs, which have poten...
05-28 11:00
Monte Rosa Therapeutics Q1 EPS $0.57 Beats $(0.30) Estimate, Sales $84.93M Beat $14.25M Estimate
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $(0.30) by 290 percent. This is a 207.55 percent increase over losses of $(0.53) per share
05-08 19:24
